Fig 2.

Survival curves of mice inoculated intracranially with C. neoformans H99 at 1,335 CFU CFU/animal. Antifungal therapy with miltefosine (MTF) began at 1 h following infection, while therapy with fluconazole (FLC) and amphotericin B (AMB) was initiated at 1 day postchallenge. Therapy with miltefosine at doses of 1.8, 3.6, and 7.2 mg/kg (A) continued through day 4, and therapy with miltefosine at 15 and 45 mg/kg (B) or with fluconazole and amphotericin B (C) continued through day 10 (n = 10 mice per group). *, P < 0.05 for median survival compared to untreated controls; §, P < 0.05 for percent survival at study endpoint compared to untreated controls.